Press release
Parkinson's Disease Clinical Trials Analysis 2024: EMA, PDMA, FDA Approvals, Pipeline, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Rotigotine, LY03003, LY3884961, More
Parkinson's Disease companies are Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, and others(Albany, USA) DelveInsight's, "Parkinson's Disease Pipeline Insight, 2024" report provides comprehensive insights about 140+ companies and 150+ pipeline drugs in Parkinson's Disease pipeline landscape. It covers the pipeline drug profiles, including Parkinson's Disease clinical trial and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To know more about the Parkinson's Disease pipeline report offerings, click here @ Parkinson's Disease pipeline outlook [https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key takeaways from the Parkinson's Disease Pipeline Insight Report
* DelveInsight's Parkinson's disease pipeline report depicts a robust space with 140+ active players working to develop 150+ pipeline therapies for Parkinson's Disease treatment.
* The leading Parkinson's Disease Companies include Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences, Orpheris, Inc., Alkahest, Inc, and others.
* Promising Parkinson's Disease Drugs Pipeline in various stages of development include Rotigotine, extended-release microspheres, LY03003, LY3884961, Methylprednisolone, Sirolimus, VY-AADC02, ERE-120: AAV2-NTN, Liatermin, MEDI1341, and others.
* The Parkinson's Disease Companies and academics that are working to assess challenges and seek opportunities that could influence Parkinson's disease R&D. The Parkinson's Disease pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.
Request for Sample report @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights
Parkinson's Disease Overview
Parkinson's disease is a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine. Studies have shown that symptoms of Parkinson's develop in patients with an 80 percent or greater loss of dopamine-producing cells in the substantia nigra. Normally, dopamine operates in a delicate balance with other neurotransmitters to help coordinate the millions of nerve and muscle cells involved in movement.
Recent Developmental Activities in the Parkinson's Disease Treatment Landscape
* In December 2021, Pharma Two B Ltd., announced that its Phase III double-blind, active-controlled study of P2B001 in early Parkinson's disease successfully met its primary and key secondary endpoints in the Phase III study, P2B001 was superior to each of its individual components as measured by the change from baseline to week 12 in total Unified Parkinson's Disease Rating Scale (UPDRS Part II and III; primary endpoint). P2B001 was superior to the pramipexole component by 2.66 points (p=0.0018) and superior to the rasagiline component by 3.30 points (p=0.0001).
* In December 2021, UCB announced that it has entered into a global co-development and co-commercialization agreement with Novartis covering UCB0599, a potential first in class, small molecule, alpha-synuclein misfolding inhibitor currently in Phase 2 clinical development, and upon completion of the ongoing Phase 1 program, an opt-in to co-develop UCB7853, an anti-alpha-synuclein antibody, both in Parkinson's Disease (PD).
Request for Sample report @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights
Parkinson's Disease Emerging Drugs Profile
Tavapadon: Cerevel Therapeutics
Tavapadon was designed to improve motor symptoms in Parkinson's disease by selectively targeting and binding to dopamine D1/D5 receptor subtypes. Tavapadon differentially activates the direct motor pathway, potentially driving motor benefit while minimizing side effects typical of drugs that non-selectively stimulate dopamine, such as daytime sedation, or somnolence, compromised impulse control and risk of psychotic symptoms including hallucinations. Tavapadon is also designed to activate the D1/D5 receptor subtypes at levels that maximize motor benefit while reducing the prolonged receptor overexcitation and desensitization caused by full agonists, which can lead to dyskinesias and exacerbation of "off" time. Currently, it is in Phase III stage of clinical trial evaluation to treat Parkinson disease.
PT320: Peptron
PT320 is a sustained-release Exenatide (GLP1 agonist) for biweekly injection (Q2W). Due to its short half-life of 2.4 hours in the plasma of Exenatide, Peptron has developed a long-acting SR-Exenatide (PT320), resulting in sustained elevations of Exenatide for 20 days. With the result of preclinical and Phase I study of PT320, Peptron is testing the efficacy of PT320 of Parkinson's disease in the on-going Phase II trial.
Parkinsons Disease Therapeutics Assessment
There are approx. 140+ key companies which are developing the therapies for Parkinson's disease. The companies which have their Parkinson's disease drug candidates in the most advanced stage, i.e. phase III include, Cerevel Therapeutics.
Request for Sample report @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights
Scope of the Parkinson's Disease Pipeline Report
* Coverage- Global
* Parkinson's Disease Companies- Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics, Cerevance, Aspen Neuroscience, Prilenia Therapeutics, Cortexyme Inc., Gain Therapeutics, Clexio Biosciences, Orpheris, Inc., Alkahest, Inc., and many others.
* Parkinson's Disease Drugs- Rotigotine, extended-release microspheres, LY03003, LY3884961, Methylprednisolone, Sirolimus, VY-AADC02, ERE-120: AAV2-NTN, Liatermin, MEDI1341, and others.
Request for Sample Report @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights
Table of Content
* Introduction
* Parkinson's Disease Executive Summary
* Parkinson's Disease: Overview
* Parkinson's Disease Pipeline Therapeutics
* Parkinson's Disease Therapeutic Assessment
* Parkinson's Disease - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Tavapadon: Cerevel Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Prasinezumab : Roche
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* MEDI1341: AstraZeneca
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Neural microtissues: Treefrog Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Parkinson's Disease Key Companies
* Parkinson's Disease Key Products
* Parkinson's Disease- Unmet Needs
* Parkinson's Disease- Market Drivers and Barriers
* Parkinson's Disease- Future Perspectives and Conclusion
* Parkinson's Disease Analyst Views
* Parkinson's Disease Key Companies
* Appendix
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=parkinsons-disease-clinical-trials-analysis-2024-ema-pdma-fda-approvals-pipeline-therapies-mechanism-of-action-route-of-administration-by-delveinsight-rotigotine-ly03003-ly3884961-more]
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parkinson's Disease Clinical Trials Analysis 2024: EMA, PDMA, FDA Approvals, Pipeline, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Rotigotine, LY03003, LY3884961, More here
News-ID: 3523441 • Views: …
More Releases from ABNewswire

Sharon Winters' Cutted Chicken in Shanghai: A Memoir of Culture, Connection, and …
Part travelogue, part love letter, Sharon Winters' memoir, Cutted Chicken in Shanghai, captures the humor, heart, and unforgettable adventures of living abroad, exploring culture, and finding friendship in a city that became her second home.
Image: https://lh7-rt.googleusercontent.com/docsz/AD_4nXcUSnDEgw0nvf5H8gQ5JKqAIwQYLCNTRZJ_yCxIdO0BXgsLKeaKi-tXagC1YO4RBaDh2FFVuoPY_vqQIm69AwJY9ThWHrm_TOyqwbugdyNAthxC5-FqO0iqzQXeBXC2hEOa_mFHmA?key=WndQkMaC4xuBkMMS4ys0zQ
Sharon Winters is a retired English and Math teacher, world traveler, humorist, and award-winning author whose writing blends wit, heart, and a love of adventure. A multi-faceted talent with a gift for turning everyday encounters…

Viltrox Joins the L-Mount Alliance, Expanding Creative Possibilities
Standardized lens mount is already supported by Leica, SIGMA, Pansonic, and more
Shenzhen, China - September 3rd, 2025 - Viltrox is proud to announce it has joined the L-Mount Alliance. This reinforces Viltrox's commitment to delivering accessible, high-performance tools for creators, and to advancing the L-Mount standard. This collaboration empowers Viltrox to design L-Mount products that open new creative horizons for both photographers and filmmakers.
Viltrox now stands alongside the alliance's founding…

Acute Liver Failure Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acute Liver Failure pipeline constitutes 5+ key companies continuously working towards developing 5+ Acute Liver Failure treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Acute Liver Failure Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…

Gastric Cancer Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emergin …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Gastric Cancer pipeline constitutes 200+ key companies continuously working towards developing 220+ Gastric Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Gastric Cancer Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gastric Cancer Market.
The Gastric Cancer Pipeline report…
More Releases for Parkinson
Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025?
The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.…
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period?
The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
Wolff Parkinson White Syndrome Treatment Market Overview 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Wolff Parkinson White Syndrome Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $1.43 billion…
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%.
Increasing Geriatric Population Driving Demand:
The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,…